Расширенный поиск

Современные ингаляционные устройства для лечения респираторной патологии: отчет рабочей группы Европейского респираторного общества и Международного общества по использованию аэрозолей в медицине

Полный текст:


По материалам: Laube B.L., Janssens H.M., de Jongh F.H. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 2011; 37 (6): 1308–1331.

Об авторе

статья Редакционная


Список литературы

1. Global Initiative for Asthma (GINA), National Heart Lung and Blood Institute, National Institutes of Health. GINA report. Global strategy for asthma management and prevention. Bethesda: National Institutes of Health; 2006.

2. Global Initiative for Obstructive Lung Disease (GOLD), National Heart Lung and Blood Institute, National Institutes of Health. GOLD report. Global strategy for diagnosis, management and prevention of COPD. Bethesda: National Institutes of Health; 2009.

3. BTS / SIGN. British guidelines on the management of asthma. London; Edinburgh: British Thoracic Society and Scottish Intercollegiate Guidelines Network; 2008.

4. Flume P.A., O'Sullivan B.P., Robinson K.A. et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am. J. Respir. Crit. Care Med. 2007; 176: 957–969.

5. Heijerman H., Westerman E., Conway S. et al. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J. Cyst. Fibros. 2009; 8: 295–315.

6. Brocklebank D., Ram F., Wright J. et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airway disease; a systematic review of the literature. Hlth Technol. Assoc. 2001; 5: 1–149.

7. Dolovich M.B., Ahrens R.C., Hess D.R. et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians / American College of Asthma, Allergy, and Immunology. Chest 2005; 127: 335–371.

8. Crompton G.K., Barnes P.J., Broeders M. et al. The need to improve inhalation technique in Europe: a report by the Aerosol Drug Management Improvement Team. Respir. Med. 2006; 100: 1479–1494.

9. Chrystyn H., Price D. Not all asthma inhalers are the same: factors to consider when prescribing a new inhaler. Prim. Care Respir. J. 2009; 18: 243–249.

10. Molimard M., Raherison C., Lignot M. et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J. Aerosol Med. 2003; 16: 249–254.

11. Lavorini F., Magnan A., Dubus J.C. et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir. Med. 2008; 102: 593–604.

12. Crompton G.K. Problems patients have using pressurized aerosol inhalers. Eur. J. Respir. Dis. 1982; 63: 101–104.

13. Labiris N.R., Dolovich M.B. Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br. J. Clin. Pharmacol. 2003; 56 (6): 588–599.

14. Köbrich R., Rudolf G., Stahlhofen W. A mathematical model of mass deposition in man. Ann. Occup. Hyg. 1994; 38: 15–23.

15. Williamson I.J., Matusiewicz S.P., Brown P.H. et al. Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. Eur. Respir. J. 1995; 8: 590–592.

16. Newman S.P., Pavia D., Garland N. et al. Effects of various inhalation modes on the deposition of radioactive pressurized aerosols. Eur. J. Respir. Dis. Suppl 1982; 63: 57–65.

17. Usmani O.S., Biddiscombe M.F., Barnes P.J. Regional lung deposition and bronchodilator response as a function of beta-2 agonist particle size. Am. J. Respir. Crit. Care Med. 2005; 172: 1497–1504.

18. Pauwels R., Newman S., Borgstrom L. Airway deposition and the airway effects of antiasthma drugs delivered from metered-dose inhalers. Eur. Respir. J. 1997; 10: 2127–2138.

19. Laube B.L. In vivo measurements of aerosol dose and distribution: clinical relevance. J. Aerosol Med. 1996; 9 (Suppl. 1): S77–S91.

20. Laube B.L. The expanding role of aerosols in systemic drug delivery, gene therapy and vaccination. Respir. Care 2005; 50: 1162–1176.

21. Ilowite J.S., Gorvoy J.D., Smaldone G.C. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am. Rev. Respir. Dis. 1987; 136: 1445–1449.

22. Dolovich M., Sanchis J., Rossman C. et al. Aerosol penetrance: a sensitive index of peripheral airways obstruction. J. Appl. Physiol. 1976; 40: 468–471.

23. Dolovich M., Killian D., Wolff R. et al. Pulmonary aerosol deposition in chronic bronchitis: IPPB versus quiet breathing. Am. Rev. Respir. Dis. 1977; 115: 397–402.

24. Carstairs H.R., Nimmo A.J., Barnes P.J. Autoradiographic visualization of b-adrenoceptor subtype in human lung. Am. Rev. Respir. Dis. 1985; 132: 541–547.

25. Mak J.C., Barnes P.J. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung. Am. Rev. Respir. Dis. 1990; 141: 1559–1568.

26. Adcock I.M., Gilbey T., Gelder C.M. et al. Glucocorticoid receptor localization in normal and asthmatic lung. Am. J. Respir. Crit. Care Med. 1996; 154: 771–782.

27. Hogg J.C., Chu F., Utokaparch S. et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 2645–2653.

28. Barnes P.J. Corticosteroids: the drugs to beat. Eur. J. Pharmacol. 2006; 533: 2–14.

29. Chua H.L., Collis G.G., Newbury A.M. et al. The influence of age on aerosol deposition in children with cystic fibrosis. Eur. Respir. J. 1994; 7: 2185–2191.

30. Brennan V.K., Osman L., Graham H. et al. Device compliance: the need to consider both competence and contrivance. Respir. Med. 2005; 99: 97–102.

31. Shim C., Williams M.H. The adequacy of inhalation of aerosol from canister nebulizers. Am. J. Med. 1980; 69: 891–894.

32. Stoloff S.W., Stempel D.A., Meyer J. et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J. Allergy Clin. Immunol. 2004; 113: 245–251.

33. Charles T., Quinn D., Weatherall M. et al. An audiovisual reminder function improves adherence with inhaled corticosteroid therapy in asthma. J. Allergy Clin. Immunol. 2007; 119: 811–816.

34. Chapman K.R., Voshaar T.H., Virchow J.C. Inhaler choice in primary care. Eur. Respir. Rev. 2005; 14: 117–122.

35. Broeders M.E., Sanchis J., Levy M.L. et al. The ADMIT series – Issues in inhalation therapy. 2) Improving technique and clinical effectiveness. Prim. Care Respir. J. 2009; 18: 76–82.

36. Maugh T.H. 2nd. FDA phasing out asthma inhalers using CFC propellant. Date last updated: April 13, 2010. Date lastaccessed: March, 29, 2011.

37. Gabrio B.J., Stein S.W., Velsaquez D.J. A new method to evaluate plume characteristics of hydrofluoroalkane and chlorofluorocarbon metered dose inhalers. Int. J. Pharm. 1999; 186: 3–12.

38. Leach C.L., Davidson P.J., Boudreau R.J. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur. Respir. J. 1998; 12: 1346–1353.

39. Leach C.L., Davidson P.J., Hasselquist B.E. et al. Lung deposition of hydrofluoroalkane 134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross over study in healthy volunteers. Chest 2002; 122: 510–516.

40. Busse W.W., Brazinsky S., Jacobson K. et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J. Allergy Clin. Immunol.1999; 104: 1215–1222.

41. Leach C.L., Davidson P.J., Hasselquist B.E. et al. Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone for a metered dose inhaler. J. Aerosol Med. 2005; 18: 379–385.

42. Bousquet J., Poli G., Acerbi D. et al. Systemic exposure and implications for lung deposition with extrafine hydrofluroalkane beclomethasone dipropionate / formoterol combinations. Clin. Pharmacokinet. 2009; 48: 347–358.

43. Papi A., Paggiaro P., Nicolini G. et al. Beclomethasone/formoterol vs fluticasone / salmeterol inhaled combination in moderate to severe asthma. Allergy 2007; 62: 1182–1188.

44. Papi A., Paggiaro P.L., Nicolini G. et al. Beclomethasone / formoterol versus budesonide / formoterol combination therapy in asthma. Eur. Respir. J. 2007; 29: 682–689.

45. Newman S.P., Weisz A.W., Talaee N. et al. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 1991; 46: 712–716.

46. Fergusson R.J., Lenney J., McHardy G.J. et al. The use of a new breath-actuated inhaler by patients with severe airflow obstruction. Eur. Respir. J. 1991; 4: 172–174.

47. Barry P.W., O'Callaghan C. Inhalational drug delivery from seven different spacer devices. Thorax 1996; 51: 835–840.

48. Richards J., Hirst P., Pitcairn G. et al. Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. J. Aerosol Med. 2001; 14: 197–208.

49. Roller C.M., Zhang G., Troedson R.G. et al. Spacer inhalation technique and deposition of extrafine aerosol in asthmatic children. Eur. Respir. J. 2007; 29: 299–306.

50. Devadason S.G., Huang T., Walker S. et al. Distribution of technetium-99m-labelled QVAR delivered using an Autohaler device in children. Eur. Respir. J. 2003; 21: 1007–1011.

51. Lavorini F., Fontana G. Targeting drugs to the airways: the role of spacer devices. Exp. Opin. Drug Deliv. 2009; 6: 91–102.

52. Cohen H.A., Cohen Z., Pomeranz A.S. et al. Bacterial contamination of spacer devices used by asthmatic children. J. Asthma 2005; 42: 169–172.

53. Cole C.H. Special problems in aerosol delivery: neonatal and pediatric considerations. Respir. Care 2000; 45: 646–651.

54. Wildhaber J.H., Waterer G.W., Hall G.L. et al. Reducing electrostatic charge on spacer devices and bronchodilator response. Br. J. Clin. Pharmacol. 2000; 50: 277–280.

55. Pierart F., Wildhaber J.H., Vrancken I. et al. Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery. Eur. Respir. J. 1999; 13: 673–678.

56. Janssens H.M., Heijnen E.M.E.W., Jong de V.M. et al. Aerosol delivery from spacers in wheezy infants aged 0 to 2 years in daily life. Eur. Respir. J. 2000; 16: 850–856.

57. Barry P.W., O'Callaghan C. The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler. Br. J. Clin. Pharmacol. 1995; 40: 76–78.

58. Schulte M., Osseiran K., Betz R. et al. Handling of and preferences for available dry powder inhaler systems by patients with asthma and COPD. J. Aerosol Med. Pulm. Drug Deliv. 2008; 21: 321–328.

59. Moore A.C., Stone S. Meeting the needs of patients with COPD: patients' preference for the Diskus inhaler compared with the Handihaler. Int. J. Clin. Pract. 2004; 58: 444–450.

60. Wilson D.S., Gillion M.S., Rees P.J. Use of dry powder inhalers in COPD. Int. J. Clin. Pract. 2007; 61: 2005–2008.

61. Meakin B.J., Cainey J.M., Woodcock P.M. Simulated ''in use'' and ''mis-use'' aspects of the delivery of terbutaline sulphate from the Bricanyl TurbohalerTM dry powder inhaler. Int. J. Pharm. 1995; 119: 103–108.

62. Clark A.R., Hollingworth A.M. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers – implications for in vitro testing. J. Aerosol Med. 1993; 6: 99–110.

63. Chrystyn H. Effects of device design on patient compliance: comparing the same drug in different devices. In: Dalby R.N., Byron P.R., Peart J. et al., eds. Respiratory drug delivery Europe 2009. River Grove, Davis Healthcare International Publishing; 2009: 105–116.

64. Chrystyn H., Price D. What you need to know about inhalers and how to use them. Prescriber 2009; 20: 47–52.

65. Everard M.L., Devadason S.G., Le Souëf P.N. Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir. Med. 1997; 91: 624–628.

66. Kamin W.E.S., Genz T., Roeder S. et al. Mass output and particle size distribution of glucocorticosteroids emitted from different inhalation devices depending on various inspiratory parameters. J. Aerosol. Med. 2002; 15: 65–73.

67. Pedersen S., Hansen O.R., Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch. Dis. Child. 1990; 65: 308–319.

68. Fenton C., Keating G.M., Plosker G.L. Novolizer: a multidose dry powder inhaler. Drugs 2003; 63: 2437–2445.

69. Koskela T., Malmström K., Sairanen U. et al. Efficacy of salbutamol via Easyhaler unaffected by low inspiratory flow. Respir. Med. 2000; 94: 1229–1233.

70. Newhouse M.T., Nantel N.P., Chambers C.B. et al. Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low flow rates. Chest 1995; 115: 952–956.

71. Nielsen K.G., Auk I.L., Bojsen K. et al. Clinical effect of Diskus drypowder inhaler at low and high inspiratory flow rates in asthmatic children. Eur. Respir. J. 1998; 11: 350–354.

72. Chodosh S., Flanders J.S., Kesten S. et al. Effective delivery of particles with the Handihaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J. Aerosol. Med. 2001; 14: 309–315.

73. Nielsen K.G., Skov M., Klug B. et al. Flow dependent effect of formoterol dry-powder inhaled from Aerolizer. Eur. Respir. J. 1997; 10: 2105–2109.

74. Bentur L., Mansour Y., Hamzani Y. et al. Measurement of inspiratory flow in children. Pediatr. Pulmonol. 2004; 38: 304–307.

75. Jarvis S., Ind P.W., Shiner R.J. Inhaled therapy in elderly COPD patients; time for re-evaluation? Age and Ageing 2007; 36: 213–218.

76. Pedersen S. How to use a rotahaler. Arch. Dis. Child. 1986; 61: 11–14.

77. Boe L., Dennis J.H., O'Driscoll B.R. et al. European Respiratory Society task force on the use of nebulizers. Eur. Respir. J. 2001; 18: 228–242.

78. Smith E.C., Denyer J., Kendrick A.H. Comparison of 23 nebulizer / compressor combinations for domiciliary use. Eur. Respir. J. 1995; 8: 1214–1221.

79. Kendrick A.H., Smith E.C., Wilson R.S.E. Selecting and using nebulizer equipment. Thorax 1997; 52: S92–S101.

80. Brand P., Beckmann H., Maas Enriquez M. et al. Peripheral deposition of a1-protease inhibitor using commercial inhalation devices. Eur. Respir. J. 2003; 22: 263–267.

81. Niven R.W., Ip A.Y., Mittleman S. et al. Some factors associated with the ultrasonic nebulization of proteins. Pharmacol. Res. 1995; 12: 53–59.

82. Munster A.M., Benstrup E., Jensen J.I. et al. Jet and ultrasonic nebulization of chain urokinase plasminogen activator (scu-PA). J. Aerosol. Med. 2000; 13: 325–333.

83. Denyer J., Nikander K., Smith N.J. Adaptive aerosol delivery (AAD) technology. Expert. Opin. Drug. Deliv. 2004; 1: 165–176.

84. Wagner A., Vorauer-Uhl K., Katinger H. Nebulization of liposomal rh-Cu/Zn-SOD with a novel vibrating membrane nebulizer. J. Liposome Res. 2006; 16: 113–125.

85. Elhissi A.M., Karnam K.K., Danesh-Azari M.R. et al. Formulations generated from ethanol-based proliposomes for delivery via medical nebulizers. J. Pharm. Pharmacol. 2006; 58: 887–894.

86. Kleemann E., Schemhl T., Geesler T. et al. Iloprost-containing liposomes for aerosol application in pulmonary arterial hypertension: formulation aspects and stability. Pharmacol. Res. 2007; 24: 277–287.

87. Johnson J., Waldrep J.C., Guo J. et al. Aerosol delivery of recombinant human DNAse I: in vitro comparison of a vibrating mesh nebulizerwith a jet nebulizer. Respir. Care 2008; 53: 1703–1708.

88. Smaldone G.C., Berg E., Nikander K. Variation in pediatric aerosol delivery: importance of facemask. J. Aerosol Med. 2005; 18: 354–363.

89. Sangwan S., Gurses B.K., Smaldone G.C. Face masks and facial deposition of aerosols. Pediatr. Pulmonol. 2004; 37: 447–452.

90. Erzinger S., Schueepp K.G., Brooks-Wildhaber J. et al. Face masks and aerosol delivery in vivo. J. Aerosol Med. 2007; 20 (Suppl. 1): S78–S84.

91. Smaldone G.C., Sangwan S., Shah A. Face mask design, facial deposition, and delivered dose of nebulized aerosols. J. Aerosol Med. 2007; 20 (Suppl. 1): S66–S77.

92. National Asthma Education and Prevention Program, National Institutes of Health: Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Bethesda: National Institutes of Health; 2007.

93. Zierenberg B., Eicher J., Dunne S. et al. Boehringer Ingelheim nebulizer BINEB1 a new approach to inhalation therapy. In: Dalby R., Byron P.R., Farr S.J., eds. Respiratory Drug Delivery V. Buffalo Grove: Interpharm Press; 1996: 187–193.

94. Zierenberg B. Optimizing the in vitro performance of Respimat. J. Aerosol Med. 1999; 12: S19–S24.

95. Newman S.P., Steed K.P., Reader S.J. Efficient delivery to the lungs of flunisolide aerosol from a new portable handheld multidose nebulizer. J. Pharm. Sci. 1996; 85: 960–964.

96. Newman S.P., Brown J., Steed K.P. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines. Comparison of Respimat1 Soft MistTM Inhaler with conventional pMDIs with and without spacer devices. Chest 1998; 113: 957–963.

97. Steed K.P., Towse L.J., Freund B. et al. Lung and oropharyngeal depositions of fenoterol hydrobromide delivered from the prototype III hand-held multidose Respimat nebuliser. Eur. J. Pharm. Sci. 1997; 5: 55–61.

98. Bateman E.D., Boushey H.A., Bousquet J. et al. GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control Study. Am. J. Respir. Crit. Care Med. 2004; 170: 836–844.

99. Donaldson S.H., Bennett W.D., Zeman K.L. et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N. Engl. J. Med. 2006; 354: 241–250.

100. Kesser K.C., Geller D.E. New aerosol delivery devices for cystic fibrosis. Respir. Care 2009; 54: 754–767.

101. Lipworth B.J. Treatment of acute asthma. Lancet 1997; 350: 18–23.

102. Corbridge T.C., Hall J.B. The assessment and management of adults with status asthmaticus. Am. J. Respir. Crit. Care Med. 1995; 151: 1296–1316.

103. Salmeron S., Taravella O., Bard M. et al. Modes d'administration des b-agonistes dans l'asthme. [Modes of administration of bagonists in asthma.]. Rev. Pneumol. Clin. 1996; 52: 119–127.

104. Hendeles L., Hatton R.C., Coors T.J. et al. Automatic replacement of albuterol nebulizer therapy by metereddose inhaler and valved holding chamber. Am. J. Hlth Syst. Pharm. 2005; 62: 1053–1061.

105. Jasper A.C., Mohsenifar Z., Kahan S. et al. Cost benefit comparison of aerosol bronchodilator delivery methods in hospitalized patients. Chest 1987; 91: 614–618.

106. Turner J.R., Corkery K.J., Eckman D.E. et al. Equivalence of continuous flow nebuliser and metered dose inhaler with reservoir bag for treatment of acute airflowobstruction. Chest 1988; 93: 476–481.

107. Mestitz H., Copland J.M., McDonald C.F. Comparison of outpatient nebulized vs. metered dose inhaler terbutaline in chronic airflow obstruction. Chest 1989; 96: 1237–1240.

108. Shortfall S.P., Blum J., Oldenburg F.A. et al. Treatment of patients hospitalized for exacerbations of chronic obstructive pulmonary disease: comparison of an oral / metereddose inhaler regimen and an intravenous/nebulizer regimen. Respir. Care 2002; 47: 154–158.

109. Robinson T.D., Freiberg D.B., Regnis J.A. et al. The role of hypoventilation and ventilation-perfusion redistribution in oxygen-induced hypercapnia during acute exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161: 1524–1529.

110. Durrington H.J., Flubacher M., Ramsay C.F. et al. Initial oxygen management in patients with an exacerbation of chronic obstructive pulmonary disease. Quart. J. Med. 2005; 98: 499–504.

111. Zhang L., Mendoza-Sassi R.A., Wainwright C. et al. Nebulized hypertonic saline solution for acute bronchiolitis in infants. Cochrane Database Syst. Rev. 2008; 4: CD006458.

112. Lenney W., Boner A.L., Bont L. et al. Medicines used in respiratory diseases only seen in children. Eur. Respir. J. 2009; 34: 531–551.

113. European Medicines Agency. Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Date last updated: March 19, 2008. Date last accessed: March 24, 2011.

114. Cates C.J., Crilly J.A., Rowe B.H. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst. Rev. 2006; 2: CD000052.

115. Dhand R. Inhalation therapy with metered-dose inhalers and dry powder inhalers in mechanically ventilated patients. Respir. Care 2005; 50: 1331–1345.

116. Dhand R., Duarte A.G., Jubran A. et al. Dose-response to bronchodilator delivered by metered-dose inhaler in ventilatorsupported patients. Am. J. Respir. Crit. Care Med. 1996; 154: 388–393.

117. Fink J.B., Dhand R., Duarte A.G. et al. Aerosol delivery from a metered-dose inhaler during mechanical ventilation. An in vitro model. Am. J. Respir. Crit. Care Med. 1996; 154: 382–387.

118. Mouloudi E., Katsanoulas K., Anastasaki M. et al. Bronchodilator delivery by metered dose inhaler in mechanically ventilated COPD patients: influence of tidal volume. Intens. Care Med. 1999; 25: 1215–1221.

119. Waldrep J.C., Keyhani K., Black M. et al. Operating characteristics of 18 different continuous-flow jet nebulizers with beclomethasone dipropionate liposome aerosol. Chest 1994; 105: 106–110.

120. Hess D.R., Dillman C., Kacmarek R.M. In-vitro evaluation of aerosol bronchodilator delivery during mechanical ventilation: pressure-control versus volume control ventilation. Intens. Care Med. 2003; 29: 1145–1150.

121. Vecellio L., Guerin C., Grimbert D. et al. In vitro study and semiempirical model for aerosol delivery control during mechanical ventilation. Intens. Care Med. 2005; 31: 871–876.

122. O'Riordan T.G., Greco M.J., Perry R.J. et al. Nebulizer function during mechanical ventilation. Am. Rev. Respir. Dis. 1992; 145: 1117–1122.

123. Miller D.D., Amin M.M., Palmer L.B. et al. Aerosol delivery and modern mechanical ventilation: in vitro / in vivo evaluation. Am. J. Respir. Crit. Care Med. 2003; 168: 1205–1209.

124. Goode M.L., Fink J.B., Dhand R. et al. Improvement in aerosol delivery with helium-oxygen mixture during mechanical ventilation. Am. J. Respir. Crit. Care Med. 2001; 163: 109–114.

125. Duarte A.G., Momii K., Bidani A. Bronchodilator therapy with metered-dose inhaler and spacer versus nebulizer in mechanically-ventilated patients: comparison of magnitude and duration of response. Respir. Care 2000; 45: 817–823.

126. Manthous C.A., Hall J.B., Schmidt G.A. et al. Metereddose inhaler versus nebulized albuterol in mechanicallyventilated patients. Am. Rev. Respir. Dis. 1993; 148: 1567–1570.

127. Bernasconi M., Brandolese R., Poggi R. et al. Doseresponse effects and time course of effects of inhaled fenoterol on respiratory mechanics and arterial oxygen tension in mechanically ventilated patients with chronic airflow obstruction. Intens. Care Med. 1990; 16: 108–114.

128. Putensen C., Hormann C., Kleinsasser A. et al. Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 1998; 157: 1743–1747.

129. Walmrath D., Schneider T., Schermuly R. et al. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 1996; 153: 991–996.

130. Hess D.R. The mask for noninvasive ventilation: principles of design and effects on aerosol delivery. J. Aerosol Med. 2007; 20 (Suppl. 1): S85–S99.

131. Branconnier M.P., Hess D.R. Albuterol delivery during noninvasive ventilation. Respir. Care 2005; 50: 1649–1653.

132. Calvert L.D., Jackson J.M., White J.A. et al. Enhanced delivery of nebulised salbutamol during non-invasive ventilation. J. Pharm. Pharmacol. 2006; 58: 1553–1557.

133. Haughney J., Price D., Barnes N.C. et al. Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir. Med. 2010; 104: 1237–1245.

134. Thomas M., Price D., Chrystyn H. et al. Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control. B.M.C. Pulm. Med. 2009; 9: 1.


Для цитирования:

Современные ингаляционные устройства для лечения респираторной патологии: отчет рабочей группы Европейского респираторного общества и Международного общества по использованию аэрозолей в медицине. Пульмонология. 2011;(6):17-41.

For citation:

. Current inhalational devices for treatment of respiratory disease. Task Force report of European Respiratory Society and the International Societyfor Aerosols in Medicine. PULMONOLOGIYA. 2011;(6):17-41. (In Russ.)

Просмотров: 738

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution-NonCommercial 4.0 International.

ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)